Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valeria Shlyakhto"'
Autor:
Stefanie Kreutmair, Lena Johanna Lippert, Cathrin Klingeberg, Corinna Albers-Leischner, Salome Yacob, Valeria Shlyakhto, Tony Mueller, Alina Mueller-Rudorf, Chuanjiang Yu, Sivahari Prasad Gorantla, Cornelius Miething, Justus Duyster, Anna Lena Illert
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The NPM-ALK fusion kinase is expressed in 60% of systemic anaplastic large-cell lymphomas (ALCL). A Nuclear Interaction Partner of ALK (NIPA) was identified as a binding partner of NPM-ALK. To identify the precise role of NIPA for NPM-ALK-driven lymp
Externí odkaz:
https://doaj.org/article/10e48b350181413cbc7c7d67f9d23de4
Autor:
Valeria Shlyakhto
Publikováno v:
Journal of Science, Humanities and Arts - JOSHA. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb5e9e5f92cf18fff2e736fa4b3390d7
https://doi.org/10.17160/josha.4.3.325
https://doi.org/10.17160/josha.4.3.325
Autor:
Joerg Hasford, Lothar Kanz, Susanne Saussele, Mathias Hänel, Markus Pfirrmann, Christian Dietz, C. Falge, Cornelius F. Waller, Wolf-K. Hofmann, Ulrike Proetel, Susanne Schnittger, Benjamin Hanfstein, Jolanta Dengler, H. Einsele, Philipp Erben, Andreas Neubauer, Michael Pfreundschuh, Michael Kneba, Gabriela M. Baerlocher, Rüdiger Hehlmann, J. Schubert, Martin C. Müller, Alice Fabarius, Andreas Hochhaus, Michael Lauseker, Karsten Spiekermann, Stefan W. Krause, Valeria Shlyakhto, Frank Stegelmann
Publikováno v:
Leukemia. 28:1988-1992
Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL transcript levels within the initial 3 month
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93faaf6325fdc3d1ede81793934ce066
https://doi.org/10.1038/leu.2014.153
https://doi.org/10.1038/leu.2014.153
Autor:
Martin C. Müller, Michael Lauseker, Gabriela M. Baerlocher, Jolanta Dengler, Christiane Falge, Andreas Neubauer, Michael Pfreundschuh, Andreas Hochhaus, Alice Fabarius, Mathias Hänel, Rüdiger Hehlmann, Ulrike Proetel, Susanne Schnittger, Philipp Erben, Joerg Hasford, Christian Dietz, Cornelius F. Waller, Hermann Einsele, J. Schubert, Lothar Kanz, Markus Pfirrmann, Benjamin Hanfstein, Karsten Spiekermann, Stefan W. Krause, Susanne Saussele, Michael Kneba, Valeria Shlyakhto, Wolf-Karsten Hofmann, Frank Stegelmann
Publikováno v:
Blood. 122:253-253
Introduction Early assessment of BCR-ABL transcript levels at 3 months allows the prediction of survival and may serve as a trigger for treatment intensification in CML patients with slow response to imatinib. The exact decline of BCR-ABL transcript
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a3be65b98ea119815c14ec5272aa470
https://doi.org/10.1182/blood.v122.21.253.253
https://doi.org/10.1182/blood.v122.21.253.253
Autor:
Mathias Hänel, Jolanta Dengler, Michael Lauseker, Cornelius F. Waller, Andreas Hochhaus, Andreas Neubauer, Martin Müller, Michael Kneba, Stefan W. Krause, Joerg E. A. Schubert, Gabriela M. Baerlocher, Frank Stegelmann, Karsten Spiekermann, Joerg Hasford, Lothar Kanz, Alice Fabarius, Hermann Einsele, Susanne Saussele, Rüdiger Hehlmann, Ulrike Proetel, Susanne Schnittger, Michael Pfreundschuh, Wolf-Karsten Hofmann, Philipp Erben, Markus Pfirrmann, Benjamin Hanfstein, Hans-Jochem Kolb, Valeria Shlyakhto, Christiane Falge
Publikováno v:
Blood. 120:3761-3761
Abstract 3761 Introduction: Early assessment of molecular and cytogenetic response at 3 months of imatinib treatment has been shown to predict survival and might trigger treatment intensification in slow responders who are supposed to harbor a BCR-AB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c571bd7311046b9cb4754075008df31f
https://doi.org/10.1182/blood.v120.21.3761.3761
https://doi.org/10.1182/blood.v120.21.3761.3761